NCT00212069View on ClinicalTrials.gov

Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

gemcitabine, carboplatin

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT00212069 - Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer | Biotech Hunter | Biotech Hunter